Therapy development for epilepsy and rare diseases
What we do
We are a boutique consultancy specialized in therapy development for epilepsy and rare neurodevelopmental disorders. Our team has been working on developmental and epileptic encephalopathies (DEEs) since before the term was coined, giving us unique perspective on how the field has evolved.
Within this niche, we support biopharma across the full value chain, from strategy to preclinical, clinical, regulatory, and communications. Over two decades, we have built a trusted network that helps our clients open doors, anticipate stakeholder needs, and build credibility in a complex ecosystem.
From seed-stage biotech to global pharma, we help teams make critical decisions at every stage of therapy development. Discover our services below.
Pipeline and portfolio strategy
Clinical and regulatory development support
Medical Affairs, communications and patient engagement
Featured publications
Recent insights
Featured
For the past eleven years the Loulou Foundation hosts an annual meeting where scientists and drug developers working on CDKL5 deficiency, together with representatives from patient organizations, meet to discuss the latest advances.
Here are the main news and take-home messages from the 2025 CDKL5 Forum that took place in October 27-28 in Boston